Devron R. Shah

801 total citations
8 papers, 599 citations indexed

About

Devron R. Shah is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Devron R. Shah has authored 8 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Hematology. Recurrent topics in Devron R. Shah's work include HER2/EGFR in Cancer Research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Mast cells and histamine (1 paper). Devron R. Shah is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Mast cells and histamine (1 paper). Devron R. Shah collaborates with scholars based in United Kingdom. Devron R. Shah's co-authors include Rashmi R. Shah, Joel Morganroth, Shamik Dholakia, Samantha Roberts, Simon P. Hart and Dominic L. Sykes and has published in prestigious journals such as British Journal of Clinical Pharmacology, Drug Safety and Drugs - Real World Outcomes.

In The Last Decade

Devron R. Shah

7 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Devron R. Shah United Kingdom	7	241	190	187	95	88	8	599
Yi Ling Teo Singapore	9	262 1.1×	228 1.2×	130 0.7×	80 0.8×	33 0.4×	11	625
Sachin Shah United States	13	286 1.2×	211 1.1×	172 0.9×	103 1.1×	50 0.6×	25	737
Yasuhito Fujisaka Japan	17	481 2.0×	247 1.3×	272 1.5×	78 0.8×	40 0.5×	51	885
Nicole Vivier France	9	547 2.3×	181 1.0×	148 0.8×	47 0.5×	81 0.9×	11	885
Brad Hirakawa United States	10	133 0.6×	318 1.7×	60 0.3×	50 0.5×	96 1.1×	18	566
L. Jonathan Zwi New Zealand	15	335 1.4×	314 1.7×	108 0.6×	53 0.6×	52 0.6×	31	867
May Garrett United States	14	266 1.1×	316 1.7×	376 2.0×	113 1.2×	27 0.3×	23	665
Friederike Kanefendt Germany	10	136 0.6×	124 0.7×	91 0.5×	131 1.4×	94 1.1×	21	455
Nazan Günel Türkiye	17	332 1.4×	303 1.6×	126 0.7×	109 1.1×	55 0.6×	60	836
Marisa Cañadas‐Garre Spain	19	256 1.1×	435 2.3×	175 0.9×	41 0.4×	39 0.4×	44	1.0k

Countries citing papers authored by Devron R. Shah

Since Specialization

Citations

This map shows the geographic impact of Devron R. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devron R. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devron R. Shah more than expected).

Fields of papers citing papers by Devron R. Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devron R. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devron R. Shah. The network helps show where Devron R. Shah may publish in the future.

Co-authorship network of co-authors of Devron R. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Devron R. Shah. A scholar is included among the top collaborators of Devron R. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devron R. Shah. Devron R. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Shah, Devron R., Simon P. Hart, & Dominic L. Sykes. (2025). Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database. Drugs - Real World Outcomes. 12(4). 593–606.

2.

Shah, Rashmi R. & Devron R. Shah. (2019). Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Drug Safety. 42(2). 181–198. 65 indexed citations

3.

Shah, Devron R., Shamik Dholakia, & Rashmi R. Shah. (2014). Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients. Drug Safety. 37(3). 135–149. 42 indexed citations

4.

Shah, Rashmi R., Joel Morganroth, & Devron R. Shah. (2013). Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Safety. 36(7). 491–503. 200 indexed citations

5.

Shah, Devron R., Rashmi R. Shah, & Joel Morganroth. (2013). Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy. Drug Safety. 36(6). 413–426. 111 indexed citations

6.

Shah, Rashmi R., Samantha Roberts, & Devron R. Shah. (2013). A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors. British Journal of Clinical Pharmacology. 76(3). 396–411. 27 indexed citations

7.

Shah, Rashmi R., Joel Morganroth, & Devron R. Shah. (2013). Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval). Drug Safety. 36(5). 295–316. 115 indexed citations

8.

Shah, Rashmi R. & Devron R. Shah. (2012). Personalized medicine: is it a pharmacogenetic mirage?. British Journal of Clinical Pharmacology. 74(4). 698–721. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact